Immuron Charts Path for Phase 2 Trial of IMM-529
Key Highlights
- Immuron concludes an important pre-IND meeting with the FDA regarding IMM-529, aimed at combating Clostridioides difficile infection (CDI).
- Previous clinical trials highlight the necessity for ongoing development of IMM-529.
- The company plans to submit an IND application for IMM-529 in the first half of 2025.
Melbourne, Australia - Immuron Limited (ASX: IMC; NASDAQ: IMRN), an innovative biopharmaceutical company with a global presence, is pleased to announce that it has received encouraging feedback from the United States Food and Drug Administration (FDA) regarding its pre-investigational new drug (pre-IND) submission to support the development of IMM-529.
With the FDA's guidance in hand, Immuron is preparing to submit an IND application for IMM-529, which is intended to prevent or treat Clostridioides difficile infections (CDI), expected in the first half of 2025. Following this submission, the company aims to launch a Phase 2 trial for patients affected by CDI.
The global rise in antibiotic-resistant infections has led to an increased reliance on broad-spectrum antibiotics. Unfortunately, this trend disrupts the gut microbiome, making individuals more vulnerable to opportunistic pathogens, including C. diff. Ironically, the standard treatment for CDI often involves antibiotics, which can impede the recovery of gut flora and elevate the risk of recurrence. C. diff is currently a significant threat in healthcare environments, with over 400,000 CDI cases reported annually in the U.S., resulting in more than 30,000 deaths, highlighting the urgent demand for novel treatment options.
To tackle this issue, Immuron is advancing IMM-529 as an adjunct therapy to be used alongside conventional antibiotics for both the prevention and treatment of recurrent CDI. The antibodies in IMM-529 are specifically designed to target C. diff, aiding in the elimination of the infection while facilitating the rapid restoration of a healthy gut microbiome, making it a promising oral solution for recurrent CDI cases.
In collaboration with Dr. Dena Lyras and her research team at Monash University, Immuron is also focusing on creating vaccines that generate bovine colostrum-derived antibodies. By immunizing dairy cows, they produce hyperimmune bovine colostrum (HBC), which is rich in antibodies aimed at key C. diff virulence factors. Specifically, IMM-529 targets Toxin B (TcB), as well as spores and surface proteins from the vegetative cells.
This innovative triple-target approach has produced impressive results in pre-clinical models, demonstrating (1) an 80% prevention rate of primary disease (P = 0.0052); (2) a 67% reduction in recurrence rates (P < 0.01); and (3) a 78.6% effectiveness in treating primary disease (P < 0.0001; TcB HBC). Notably, the antibodies in IMM-529 show cross-reactivity with several human C. diff strains, including hypervirulent types.
To date, IMM-529 is the only investigational therapy that has shown therapeutic potential across all three phases of CDI. Insights from opportunity assessments suggest that if IMM-529 is proven effective, it could be incorporated early into treatment protocols as deemed appropriate by insurance providers. Approximately 31,000 patients who have undergone treatment after one course each of fidaxomicin and vancomycin may qualify for the therapy, while those experiencing their first recurrence could increase the eligible patient count to 95,000. Current market evaluations estimate that the annual revenue potential for IMM-529 could reach around USD 93 million, based on conservative assumptions regarding patient eligibility and treatment uptake within the defined patient population post-second recurrence.
Experts in infectious diseases regard the oral administration of IMM-529 as a significant advantage, especially when compared to existing treatment options like bezlotoxumab and fecal microbiota transplants, which tend to be both costly and complex.
For any inquiries, please contact:
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
steve@immuron.com
About Immuron
Immuron Limited (ASX: IMC; NASDAQ: IMRN) is dedicated to developing and commercializing targeted oral therapies that focus on polyclonal antibodies for the treatment of infectious diseases.
Immuron's Innovative Technology
Immuron specializes in the production of polyclonal immunoglobulins (IgG) derived from hyper-immune bovine colostrum. This technology allows for the creation of highly specific immunoglobulins that target various enteric pathogens, with the unique advantage of being orally active. The bovine IgG can withstand stomach acid and digestive breakdown, maintaining its effectiveness within the human digestive system to directly benefit the gut microbiota.
Frequently Asked Questions
What is IMM-529 designed for?
IMM-529 is intended to prevent and treat Clostridioides difficile infections (CDI), which are a significant health concern due to antibiotic resistance.
Who is Immuron collaborating with?
Immuron is partnering with Dr. Dena Lyras and her research team at Monash University to develop the necessary antibodies for IMM-529.
What makes IMM-529 unique?
IMM-529 is the only investigational drug that has shown therapeutic potential across all three phases of C. diff disease treatment.
How does IMM-529 benefit gut health?
IMM-529 aids in clearing C. diff infections, which helps promote a quicker re-establishment of healthy gut flora.
What revenue potential does IMM-529 have?
If successful, IMM-529 could generate an estimated annual revenue of around USD 93 million in the market.
